Lung Cancer
Volume 69, Issue 3 , Pages 265-271 , September 2010

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients

  • Andreas Pircher

      Affiliations

    • Medical University Innsbruck, Department of Internal Medicine V, Hematology and Oncology, Anichstrasse 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding authors. Tel.: +43 512 504 82430; fax: +43 512 504 26299.
    • ,
  • Ferdinand Ploner

      Affiliations

    • Medical University Graz, Department of Oncology, Auenbruggerplatz 15, 8036 Graz, Austria
    • ,
  • Helmut Popper

      Affiliations

    • Medical University Graz, Institute of Pathology, Auenbruggerplatz 15, 8036 Graz, Austria
    • ,
  • Wolfgang Hilbe

      Affiliations

    • Medical University Innsbruck, Department of Internal Medicine V, Hematology and Oncology, Anichstrasse 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding authors. Tel.: +43 512 504 82430; fax: +43 512 504 26299.

Received 30 September 2009 ,Revised 18 January 2010 ,Accepted 24 January 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0169-5002(10)00060-7

doi: 10.1016/j.lungcan.2010.01.017

Lung Cancer
Volume 69, Issue 3 , Pages 265-271 , September 2010

Article Tools

* Image Usage & Resolution